Time filter

Source Type

Patent
Sinphar Tian li Pharmaceutical Co. | Date: 2017-03-29

A method for providing poria cocos extract of K2 with an increment. The method comprises the following steps:(a) mixing poria cocos with a solvent to provide a first mixture;(b) alkalifying the first mixture to obtain a second mixture;(c) acidizing the second mixture to obtain a third mixture,(d) alkalifying the third mixture to obtain a fourth mixture with a pH value greater than 7; and(e) neutralizing the fourth mixture,wherein K2 is at least one of tumulosic acid, dehydrotumulosic acid, polyporenic acid C, and 3-epi-dehydrotumulosic acid.


Patent
Sinphar Tian li Pharmaceutical Co. | Date: 2017-02-15

An isoacteoside derivative and forming method and uses thereof; the isoacteoside derivative has a structure of formula (I):_(1) and R_(2) are independently selected from hydrogen, halogen, hydroxyl and alkoxy oxyl; R_(3) and R_(4) are independently selected from hydroxyl, alkoxy oxyl and acyloxy; R_(5) is independently selected from hydroxyl or acyloxy. Drugs comprsing the isoacteoside derivative have uses of treating or preventing amyloid peptide related diseases and preventing eye lesions and the like.


A pharmaceutical composition containing isoacteoside to the acteoside is provided, which is able to inhibit formation, accumulation or aggregation of amyloid peptides, and is thus useful in preventing or treating amyloid beta peptide-associated diseases or conditions, wherein a weight ratio of the isoacteoside to the acteoside is 4:1 to 1:4.


A pharmaceutical composition containing isoacteoside to the acteoside is provided, which is able to inhibit formation, accumulation or aggregation of amyloid peptides, and is thus useful in preventing or treating amyloid beta peptide-associated diseases or conditions, wherein a weight ratio of the isoacteoside to the acteoside is 4:1 to 1:4.


Patent
Sinphar Tian li Pharmaceutical Co. | Date: 2011-03-23

A pharmaceutical composition for treating diabetes is provided in this invention. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a Poria extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The Poria extract contains 1-60% of the lanostane compounds by weight of the extract, and is devoid of secolanostane.


Patent
Sinphar Tian li Pharmaceutical Co. | Date: 2011-01-12

The present invention is related to a novel use of a lanostane having the following formula (I) or a pharmaceutically acceptable salt thereof in enhancing uptake of nutrients:_(1) is either H or CH_(3); R_(2) is OCOCH_(3), =O or OH; R_(3) is H or OH; R_(4) is -C(=CH_(2))-C(CH_(3))_(2)R_(a) or -CH=C(CH_(3))-R_(b), in which R_(a) is H or OH, and R_(b) is CH_(3) or CH_(2)OH; R_(5) is H or OH; and R_(6) is CH_(3) or CH_(2)OH.


Isoacteoside or a pharmaceutically acceptable salt thereof is used to prevent or treat amyloid beta peptide-associated diseases or conditions as an agent for inhibiting formation, accumulation or aggregation of amyloid beta peptides.


Patent
Sinphar Tian li Pharmaceutical Co. | Date: 2016-04-13

Disclosed is use of an active ingredient in the preparation of a medicament, wherein the medicament is used to increase the expression quantity of SIRT1 mRNA and/or reduce the expression quantity of SOCS3 mRNA, and it can especially it can be used to regulate blood sugar, and the active ingredient is selected from the following groups: compounds of formula (I), pharmaceutically acceptable salts of compounds of formula (I), and combinations of the foregoing. In formula (I), X is H or C1-C3 alkyl, one of Y and Z is formula (I) and the other is H, OH, or formula (I), wherein when Y is formula (I), Z is formula (I), and R1 to R13 are independently H or OH, and wherein R1 and R3 are not H at the same time, and R8 and R9 are not H at the same time.


Isoacteoside or a pharmaceutically acceptable salt thereof is used to prevent or treat amyloid beta peptide-associated diseases or conditions as an agent for inhibiting formation, accumulation or aggregation of amyloid beta peptides.


The present invention is related to a novel use of a lanostane having the following formula (I) or a pharmaceutically acceptable salt thereof in treating a disease induced from immune disorder:_(1) is either H or CH_(3); R_(2) is OCOCH_(3), =O or OH; R_(3) is H or OH; R_(4) is -C(=CH_(2))-C(CH_(3))_(2)R_(a), in which R_(a) is H or OH, or -CH=C(CH_(3))-R_(b), in which R_(b) is CH_(3) or CH_(2)OH; R_(5) is H or OH; and R_(6) is CH_(3) or CH_(2)OH.

Loading Sinphar Tian Li Pharmaceutical Co. collaborators
Loading Sinphar Tian Li Pharmaceutical Co. collaborators